{"title":"在日本用血液生物标志物测试选项模拟阿尔茨海默病的诊断流程","authors":"Ataru Igarashi, Noriyuki Kimura, Takuya Ataka, Temmei Ito, Kotaro Sasaki, Chizuru Kobayashi, Mayaka Tani, Yukinori Sakata, Mie Azuma, Ayano Chida, Tomomi Takeshima, Kosuke Iwasaki, Etsuro Matsubara","doi":"10.1002/trc2.70157","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>A dynamic simulation estimated wait times and treatment-eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness-to-pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment-eligible patients increased considerably with BBM-based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment-eligible patients.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM-based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>A dynamic simulation models Alzheimer's diagnostic workflows in Japan.</li>\n \n <li>Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.</li>\n \n <li>Implementing BBM tests improves access to Alzheimer's diagnostics.</li>\n \n <li>Study quantifies demand for diagnostic testing based on costs and accessibility.</li>\n \n <li>Testing costs impact the number of treatment-eligible Alzheimer's patients.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 4","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70157","citationCount":"0","resultStr":"{\"title\":\"Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan\",\"authors\":\"Ataru Igarashi, Noriyuki Kimura, Takuya Ataka, Temmei Ito, Kotaro Sasaki, Chizuru Kobayashi, Mayaka Tani, Yukinori Sakata, Mie Azuma, Ayano Chida, Tomomi Takeshima, Kosuke Iwasaki, Etsuro Matsubara\",\"doi\":\"10.1002/trc2.70157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>A dynamic simulation estimated wait times and treatment-eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness-to-pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment-eligible patients increased considerably with BBM-based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment-eligible patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM-based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>A dynamic simulation models Alzheimer's diagnostic workflows in Japan.</li>\\n \\n <li>Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.</li>\\n \\n <li>Implementing BBM tests improves access to Alzheimer's diagnostics.</li>\\n \\n <li>Study quantifies demand for diagnostic testing based on costs and accessibility.</li>\\n \\n <li>Testing costs impact the number of treatment-eligible Alzheimer's patients.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":53225,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"volume\":\"11 4\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70157\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70157\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan
INTRODUCTION
This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.
METHODS
A dynamic simulation estimated wait times and treatment-eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness-to-pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.
RESULTS
The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment-eligible patients increased considerably with BBM-based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment-eligible patients.
DISCUSSION
Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM-based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.
Highlights
A dynamic simulation models Alzheimer's diagnostic workflows in Japan.
Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.
Implementing BBM tests improves access to Alzheimer's diagnostics.
Study quantifies demand for diagnostic testing based on costs and accessibility.
Testing costs impact the number of treatment-eligible Alzheimer's patients.
期刊介绍：
Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
